- Home
- GGZ vs SPRO Comparison
GGZ vs SPRO Comparison
Compare GGZ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGZ
- SPRO
- Stock Information
- Founded
- GGZ 2013
- SPRO 2013
- Country
- GGZ United States
- SPRO United States
- Employees
- GGZ N/A
- SPRO N/A
- Industry
- GGZ Investment Managers
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- GGZ Finance
- SPRO Health Care
- Exchange
- GGZ Nasdaq
- SPRO Nasdaq
- Market Cap
- GGZ 109.0M
- SPRO 104.1M
- IPO Year
- GGZ N/A
- SPRO 2017
- Fundamental
- Price
- GGZ $14.39
- SPRO $2.07
- Analyst Decision
- GGZ
- SPRO Buy
- Analyst Count
- GGZ 0
- SPRO 4
- Target Price
- GGZ N/A
- SPRO $5.00
- AVG Volume (30 Days)
- GGZ 12.8K
- SPRO 721.1K
- Earning Date
- GGZ 01-01-0001
- SPRO 08-12-2025
- Dividend Yield
- GGZ 5.39%
- SPRO N/A
- EPS Growth
- GGZ N/A
- SPRO N/A
- EPS
- GGZ 1.75
- SPRO N/A
- Revenue
- GGZ N/A
- SPRO $48,576,000.00
- Revenue This Year
- GGZ N/A
- SPRO N/A
- Revenue Next Year
- GGZ N/A
- SPRO N/A
- P/E Ratio
- GGZ $6.79
- SPRO N/A
- Revenue Growth
- GGZ N/A
- SPRO N/A
- 52 Week Low
- GGZ $9.43
- SPRO $0.51
- 52 Week High
- GGZ $12.50
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- GGZ 68.32
- SPRO 48.98
- Support Level
- GGZ $14.31
- SPRO $1.83
- Resistance Level
- GGZ $14.69
- SPRO $1.94
- Average True Range (ATR)
- GGZ 0.22
- SPRO 0.10
- MACD
- GGZ 0.03
- SPRO 0.03
- Stochastic Oscillator
- GGZ 69.70
- SPRO 46.55
About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.